Additionally, the 36-month beta value for TNGX is 1.63. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TNGX is 58.92M and currently, short sellers hold a 26.60% ratio of that float. The average trading volume of TNGX on July 02, 2025 was 2.65M shares.
TNGX) stock’s latest price update
Tango Therapeutics Inc (NASDAQ: TNGX)’s stock price has increased by 6.25 compared to its previous closing price of 5.12. However, the company has seen a 1.49% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-27 that BOSTON, June 27, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines’ daraxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS(ON) G12D-selective inhibitor) in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer.
TNGX’s Market Performance
Tango Therapeutics Inc (TNGX) has experienced a 1.49% rise in stock performance for the past week, with a 145.05% rise in the past month, and a 297.08% rise in the past quarter. The volatility ratio for the week is 12.96%, and the volatility levels for the past 30 days are at 16.27% for TNGX. The simple moving average for the past 20 days is 16.88% for TNGX’s stock, with a 52.80% simple moving average for the past 200 days.
Analysts’ Opinion of TNGX
Many brokerage firms have already submitted their reports for TNGX stocks, with Jefferies repeating the rating for TNGX by listing it as a “Buy.” The predicted price for TNGX in the upcoming period, according to Jefferies is $19 based on the research report published on July 17, 2024 of the previous year 2024.
Piper Sandler gave a rating of “Overweight” to TNGX, setting the target price at $18 in the report published on February 12th of the previous year.
TNGX Trading at 92.03% from the 50-Day Moving Average
After a stumble in the market that brought TNGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.72% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNGX starting from Barry Douglas, who sale 2,774 shares at the price of $2.99 back on Feb 04 ’25. After this action, Barry Douglas now owns 68,570 shares of Tango Therapeutics Inc, valued at $8,289 using the latest closing price.
Barry Douglas, the General Counsel of Tango Therapeutics Inc, sale 2,556 shares at $3.16 during a trade that took place back on Feb 05 ’25, which means that Barry Douglas is holding 66,014 shares at $8,081 based on the most recent closing price.
Stock Fundamentals for TNGX
Current profitability levels for the company are sitting at:
- -3.56 for the present operating margin
- 0.84 for the gross margin
The net margin for Tango Therapeutics Inc stands at -3.23. The total capital return value is set at -0.61. Equity return is now at value -61.35, with -38.87 for asset returns.
Based on Tango Therapeutics Inc (TNGX), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -3.66.
Currently, EBITDA for the company is -143.1 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 13.86. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.26.
Conclusion
In conclusion, Tango Therapeutics Inc (TNGX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
